TY - JOUR
T1 - MicroRNA pharmacogenomics
T2 - Post-transcriptional regulation of drug response
AU - Rukov, Jakob Lewin
AU - Shomron, Noam
N1 - Funding Information: The authors are grateful to David Gurwitz for his valuable scientific discussions, ideas and comments on the manuscript. This work was supported by The Memorial Foundation of Eva and Henry Fraenkel, The Harboe Foundation and The Aase and Einar Danielsen Foundation (to J.R.). This work was supported by the Chief Scientist Office, Ministry of Health, Israel (3-4876), Kurz-Lion Foundation, Ori Levi Foundation for Mitochondrial Research, Israel Cancer Association and The Wolfson Family Charitable Fund to the N.S. group.
PY - 2011/8
Y1 - 2011/8
N2 - The field of pharmacogenomics aims to predict which drugs will be most effective and safe for a particular individual based on their genome sequence or expression profile, thereby allowing personalized treatment. The bulk of pharmacogenomic research has focused on the role of single nucleotide polymorphisms, copy number variations or differences in gene expression levels of drug metabolizing or transporting genes and drug targets. In this review paper, we focus instead on microRNAs (miRNAs): small noncoding RNAs, prevalent in metazoans, that negatively regulate gene expression in many cellular processes. We discuss how miRNAs, by regulating the expression of pharmacogenomic-related genes, can play a pivotal role in drug efficacy and toxicity and have potential clinical implications for personalized medicine.
AB - The field of pharmacogenomics aims to predict which drugs will be most effective and safe for a particular individual based on their genome sequence or expression profile, thereby allowing personalized treatment. The bulk of pharmacogenomic research has focused on the role of single nucleotide polymorphisms, copy number variations or differences in gene expression levels of drug metabolizing or transporting genes and drug targets. In this review paper, we focus instead on microRNAs (miRNAs): small noncoding RNAs, prevalent in metazoans, that negatively regulate gene expression in many cellular processes. We discuss how miRNAs, by regulating the expression of pharmacogenomic-related genes, can play a pivotal role in drug efficacy and toxicity and have potential clinical implications for personalized medicine.
UR - http://www.scopus.com/inward/record.url?scp=79961027715&partnerID=8YFLogxK
U2 - 10.1016/j.molmed.2011.04.003
DO - 10.1016/j.molmed.2011.04.003
M3 - مقالة مرجعية
SN - 1471-4914
VL - 17
SP - 412
EP - 423
JO - Trends in Molecular Medicine
JF - Trends in Molecular Medicine
IS - 8
ER -
